FrancophonIA/ELRC3.0 huggingface dataset:
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zessly have also been included in the summary of product characteristics and the package leaflet.
Estonian: Zessly ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The company that markets Zessly will provide an alert card for patients and educational material for prescribers, summarising the safety information about the medicine.
Estonian: Zesslyt turustav ettevõte koostab patsientidele hoiatuskaardi ja ravimi määrajatele teabematerjali, milles on kokkuvõtlik ravimi ohutusteave.
English: The active substance in Zessly, infliximab, is a monoclonal antibody (a type of protein) that attaches to a substance in the body called tumour necrosis factor alpha (TNF-α).
Estonian: Zessly toimeaine infliksimab on monoklonaalne antikeha (teatud valk), mis seondub organismis sisalduva aine kasvaja α-nekroositeguriga (TNF-α).
English: How is Zessly used?
Estonian: Kuidas Zesslyt kasutatakse?
English: Studies have also shown that giving Zessly produces similar levels of the active substance in the body to giving Remicade.
Estonian: Uuringud on samuti tõendanud, et Zessly tekitab organismis sarnase toimeainesisalduse kui Remicade.
English: Zessly must not be used in patients who are hypersensitive (allergic) to infliximab, mouse proteins or any of the other ingredients of Zessly.
Estonian: Zesslyt ei tohi kasutada patsiendid, kes on infliksimabi, hiire valkude või Zessly mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Zessly contains the active substance infliximab.
Estonian: Zessly sisaldab toimeainena infliksimabi.
English: What benefits of Zessly have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Zessly kasulikkus?
English: How does Zessly work?
Estonian: Kuidas Zessly toimib?
English: This substance is involved in causing inflammation and is found at high levels in patients with the diseases that Zessly is used to treat.
Estonian: See aine osaleb põletiku tekitamisel ning selle sisaldus on suur patsientidel, kelle haigusi ravitakse Zesslyga.
English: • psoriatic arthritis (psoriasis with inflammation of the joints).
Estonian: • psoriaatiline artriit (psoriaas koos liigesepõletikuga).
English: Laboratory studies comparing Zessly with Remicade have shown that the active substance in Zessly is highly similar to that in Remicade in terms of structure, purity and biological activity.
Estonian: Zesslyt võrreldi Remicadega laboriuuringutes, mis tõendasid, et Zessly toimeaine sarnaneb struktuuri, puhtuse ja bioloogilise toime poolest Remicade toimeainega.
English: For the full list of side effects of Zessly, see the package leaflet.
Estonian: Zessly kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: An overview of Zessly and why it is authorised in the EU
Estonian: Ülevaade ravimist Zessly ja ELis müügiloa väljastamise põhjendus
English: Zessly is a ‘biosimilar medicine'.
Estonian: Zessly on bioloogiliselt sarnane ravim.
English: The dose of Zessly and how often it is given depends on the patient's body weight and the condition being treated.
Estonian: Zessly annus ja manustamissagedus sõltuvad patsiendi kehakaalust ja ravitavast haigusseisundist.
English: Zessly is given as an infusion (drip) into a vein over 2 hours.
Estonian: Zesslyt manustatakse 2 tundi kestva veeniinfusioonina.
English: Zessly can only be obtained with a prescription and treatment should be started and supervised by a specialist doctor who has experience in the diagnosis and treatment of the diseases that Zessly is used to treat.
Estonian: Ravi sellega tohib alustada üksnes eriarst, kes on kogenud nende haiguste diagnoosimises ja ravis, mille raviks Zesslyt kasutatakse, ning ravi peab toimuma tema järelevalve all.
English: The reference medicine for Zessly is Remicade.
Estonian: Zessly võrdlusravim on Remicade.
English: • Crohn's disease (disease causing inflammation of the gut)
Estonian: • Crohni tõbi (soolepõletikku põhjustav haigus);
English: • rheumatoid arthritis (disease causing inflammation of the joints)
Estonian: • reumatoidartriit (liigesepõletikku põhjustav haigus);
English: • psoriasis (red, scaly patches on the skin)
Estonian: • psoriaas (punased ketendavad nahalaigud);
English: • ankylosing spondylitis (inflammation of spine causing back pain)
Estonian: • anküloseeriv spondüliit (seljavalu põhjustav lülisambapõletik);
English: Why is Zessly authorised in the EU?
Estonian: ELis Zesslyle väljastatud müügiloa põhjendus
English: • ulcerative colitis (inflammation and ulcers in the lining of the gut)
Estonian: • haavandiline koliit (soole limaskesta põletik ja haavandid);
English: ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
Estonian: ANNEX I NIMEDE LOETELU, RAVIMVORMID, RAVIMITE TUGEVUSED, MANUSTAMISVIISID, MÜÜGILUBADE HOIDJAD LIIKMESRIIKIDES
English: 170 09 Sverige (SWE)
Estonian: 170 09 Sverige (SWE) Rootsi
English: Bruninieku 5, Riga, LV1001, Latvia
Estonian: Bruninieku 5, Riga, LV1001, Läti
English: GSK d.o.o., Ljubljana Knezov štradon 90 SI-1000 Ljubljana Slovenija
Estonian: GSK d.o.o., Ljubljana Knezov štradon 90 SI-1000 Ljubljana Sloveenia
English: DK-3450 Allerød Denmark
Estonian: DK-3450 Allerød Taani
English: A. Goštauto g. 40A LT-01112 Vilnius, Lithuania
Estonian: A. Goštauto g. 40A LT-01112 Vilnius, Leedu
English: 152 32 Halandri, Athens
Estonian: Kifissias 266, 152 32 Halandri, Athens
English: Valeas S.p.A. via Vallisneri 10 20133 Milano
Estonian: via Vallisneri 10 20133 Milano
English: United Kingdom Beecham Group PLC SB House
Estonian: Ühendkuningriik Beecham Group PLC SB House
English: GlaxoSmithKline 100, route de Versailles78163 Marly-le-Roi Cedex
Estonian: Prantsusmaa Laboratoire GlaxoSmithKline 100, route de Versailles78163 Marly-le-Roi Cedex
English: Augmentin (80 /11.97 mg/ml) 400/57mg/ 5ml Powder for oral suspension
Estonian: Augmentin (80 /11.97 mg/ml) 400/57mg/ 5ml Pulber suukaudse suspensiooni valmistamiseks
English: Slovak Republic GlaxoSmithKline Slovakia sro., Galvaniho7/A, 82104
Estonian: GlaxoSmithKline Slovakia sro., Galvaniho7/A, 82104 Bratislava, Slovakkia
English: GlaxoSmithKline Kft. 1124 Bp, Csörsz u. 43 Hungary
Estonian: GlaxoSmithKline Kft. 1124 Bp, Csörsz u. 43
English: Glaxo Smith Kline B.V. Huis ter Heideweg 62 3705 LZ ZEIST THE NETHERLANDS
Estonian: Huis ter Heideweg 62 3705 LZ ZEIST HOLLAND
English: Middlesex TW8 9GS United Kingdom
Estonian: Middlesex TW8 9GS Ühendkuningriik
English: GlaxoSmithKline EOOD Ivan Vasov Complex Dimitar Manov street,
Estonian: GlaxoSmithKline EOOD Ivan Vasov Complex Dimitar Manov street, bl.10, 1408 Sofia, Bulgaaria
English: 500mg : 50mg/ vial
Estonian: 500mg : 50mg/ viaal
English: 1000mg : 100mg/ vial
Estonian: 1000mg : 100mg/ viaal
English: Augmentin intravenös 550 mg - Trockenstechampullen
Estonian: Augmentin intravenös 550 mgTrockenstechampullen
English: 2000mg : 200mg/ vial
Estonian: 2000mg : 200mg/ viaal
English: Powder for injection
Estonian: Pulber infusioonilahuse valmistamiseks
English: Powder for solution for injection AND Powder and solvent for solution for injection
Estonian: Pulber süstelahuse valmistamiseks ja pulber ja lahusti süstelahuse valmistamiseks
English: 125/31.25mg/ 5mlOral suspension Oral use
Estonian: 125/31.25mg/ 5mlOral suspension Suukaudne
English: Luxembourg GlaxoSmithKline s.a. / n.v. Rue du Tilleul 13
Estonian: Luksemburg GlaxoSmithKline s.a. / n.v.
English: Augmentin Intravenous 1.2g 1000/200 mg Powder for solution for injection or infusion
Estonian: Augmentin Intravenous 1.2g 1000/200 mg Pulber süstelahuse või infusioonilahuse valmistamiseks
English: 980 Great West Road Brentford, Middlesex, TW8
Estonian: 980 Great West Road Brentford, Middlesex, TW8 9GS
English: 2000/200 mg Powder for infusionIntravenous use
Estonian: 2000/200 mg Pulber infusioonilahuse valmistamiseks
English: Powder for injection or infusion
Estonian: Pulber süstelahuse või infusioonilahuse valmistamiseks
English: 1000/125 mg Powder for oral suspension
Estonian: 1000/125 mg Pulber suukaudse suspensiooni valmistamiseks
English: Clavamel 250mg/125mg Tablets
Estonian: Clavamel 250mg/125mg Tablets 250/125mg
English: 250/31.25mg Powder for oral suspension
Estonian: 250/31.25mg Pulber suukaudse suspensiooni valmistamiseks
English: 1000/100 mg Powder for injection
Estonian: 1000/100 mg Pulber infusioonilahuse valmistamiseks
English: Dispersible tablets Oral use
Estonian: Dispergeeritavad tabletid
English: Augmentin Duo 500/125 tablets
Estonian: Augmentin Duo 500/125 tablets 500/125mg
English: 125/31.25mg Powder for oral suspension
Estonian: 125/31.25mg Pulber suukaudse suspensiooni valmistamiseks
English: Beecham Group plc 980 Great West Road, Brentford, Middlesex TW8 9GS
Estonian: Beecham Group PLC 980 Great West Road, Brentford, Middlesex TW8 9G
English: Augmentin 125/31 SF Sachet 125/31.25mg Powder for oral suspension
Estonian: Augmentin 125/31 SF Sachet
English: 2000/200 mg Powder for solution for infusion
Estonian: 2000/200 mg Pulber süstelahuse valmistamiseks
English: Dispersible Tablet Oral use
Estonian: Dispergeeritav tablett
English: 1000/62.5mg modified-release tablet
Estonian: 1000/62.5mg Toimeainet modifitseeritult vabastav tablett
English: 1000/200 mg Powder for injection
Estonian: 1000/200 mg Pulber süstelahuse valmistamiseks
English: 1000/200 mg Powder for injection or infusion
Estonian: 1000/200 mg Pulber süstelahuse või infusioonilahuse valmistamiseks
English: Laboratoire
Estonian: Tablett
English: Powder for solution for infusion
Estonian: Pulber süstelahuse valmistamiseks
English: This summary was last updated: 19/11/2010
Estonian: Kokkuvõtte viimane uuendus: 19/11/2010
English: These side effects occur generally within the first week of treatment and are usually temporary and disappear once treatment has stopped.
Estonian: Kõrvalnähud esinevad tavaliselt esimese ravinädala jooksul ning on ajutised ja kaovad pärast ravi lõppu.
English: Other information about Meloxoral:
Estonian: Muu teave Meloxorali kohta:
English: It can be used for both acute disorders, such as those seen after an injury, and chronic (long term) disorders.
Estonian: Ravimit võib kasutada nii ägedate (näiteks vigastuse järel tekkivate) kui ka krooniliste (pikaajaliste) kahjustuste korral.
English: Meloxoral contains the active substance meloxicam in a strength of 0.5 mg/ml (cats) or 1.5 mg/ml (dogs) for the oral suspension.
Estonian: Suukaudne suspensioon Meloxoral sisaldab toimeainena meloksikaami tugevusega 0,5 mg/ml (kassid) või 1,5 mg/ml (koerad).
English: The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Meloxoral has been shown to be bioequivalent to Metacam.
Estonian: Veterinaarravimite komitee leidis, et Euroopa Liidu nõuete kohaselt on Meloxoral osutunud Metacamiga bioekvivalentseks.
English: People who are hypersensitive (allergic) to NSAIDs should avoid contact with Meloxoral.
Estonian: Inimesed, kes on mittesteroidsete põletikuvastaste ravimite suhtes ülitundlikud (allergilised), peavad kokkupuudet Meloxoraliga vältima.
English: How has the effectiveness of Meloxoral been studied?
Estonian: Kuidas Meloxorali efektiivsust uuriti?
English: In the case of accidental ingestion medical advice should be sought immediately, showing the package leaflet or label to the physician.
Estonian: Juhusliku neelamise korral tuleb pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
English: prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam reduces those responses.
Estonian: Et prostaglandiinid tekitavad põletikku, valu, eksudatsiooni ja palavikku, vähendab meloksikaam neid reaktsioone.
English: Therefore the CVMP's view was that, as for Metacam, Meloxoral's benefits are greater than its risks to alleviate inflammation and pain in musculo-skeletal disorders and they recommended that Meloxoral should be given a marketing authorisation.
Estonian: Sel põhjusel oli veterinaarravimite komitee seisukohal, et nagu Metacami puhul, on Meloxorali kasulikkus põletiku ja valu leevendamisel luu- ja lihaskonna kahjustuste korral suurem kui sellega kaasnevad riskid, ning soovitas anda Meloxorali müügiloa.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Meloxoral to LeVet B.V. on 19/11/2010.
Estonian: Euroopa Komisjon andis Meloxorali müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele LeVet B.V.
English: Information on the prescription status of this product may be found on the label of the carton.
Estonian: Teave selle kohta, kas toode on retseptiravim, on esitatud karbi etiketil.
English: What is Meloxoral?
Estonian: Mis on Meloxoral?
English: Why has Meloxoral been approved?
Estonian: Miks Meloxoral heaks kiideti?
English: Meloxoral is presented as a pale yellow oral suspension which is to be given mixed with food or directly into the mouth in dogs or cats.
Estonian: Meloxoral on kahvatukollane suukaudne suspensioon, mida manustatakse koertele ja kassidele toidu sisse segatuna või vahetult suhu.
English: Meloxoral contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Estonian: Meloxoral sisaldab meloksikaami, mis kuulub mittesteroidsete põletikuvastaste ravimite klassi.
English: Meloxoral is a ‘generic' which means that Meloxoral is similar to a ‘reference veterinary medicine' already authorised in the EU (Metacam).
Estonian: See tähendab, et Meloxoral on sarnane võrdlus-veterinaarravimiga, millel juba on Euroopa Liidus müügiluba (Metacam).
English: Occasional side effects of Meloxoral are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools, renal failure and apathy (lack of vitality).
Estonian: Meloxorali aeg-ajalt esinevad kõrvalnähud on samad, mida esineb mittesteroidsete põletikuvastaste ravimite kasutamisel, näiteks isutus, oksendamine, kõhulahtisus, veriroe, neerupuudlikkus ja apaatia (loidus).
English: How does Meloxoral work?
Estonian: Kuidas Meloxoral toimib?
English: Studies have been carried out to prove that Meloxoral is ‘bioequivalent' to the reference veterinary medicine which means that Meloxoral is equivalent to Metacam in the way it is absorbed and used by the body.
Estonian: Uuringute tulemusel on selgunud Meloxorali bioekvivalentsus võrdlusravimigasee tähendab, et Meloxoral imendub ja toimib organismis samamoodi nagu Metacam.
English: What is Meloxoral used for?
Estonian: Milleks Meloxorali kasutatakse?
English: In cats Meloxoral is used to alleviate inflammation and pain in chronic musculo-skeletal disorders.
Estonian: Kassidel kasutatakse Meloxorali põletiku ja valu leevendamiseks krooniliste luu- ja lihaskonna kahjustuste korral.
English: Meloxoral is used in dogs to relieve inflammation and pain in musculo-skeletal disorders.
Estonian: Meloxorali kasutatakse koertel põletiku ja valu leevendamiseks luu- ja lihaskonna kahjustuste korral.
English: What are the side-effects of Meloxoral?
Estonian: Mis kõrvalnähud Meloxoraliga kaasnevad?
English: Studies looked at how Meloxoral was absorbed and its effects in the body, in comparison with Metacam.
Estonian: Uuringutes võrreldi Meloxorali imendumist ja toimet organismis Metacami imendumise ja toimega.
English: The marketing authorisation was renewed on 24 March 2008.
Estonian: Müügiluba pikendati 24. märtsil 2008.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ytracis to CIS bio international on 24 March 2003.
Estonian: Euroopa Komisjon väljastas Ytracise müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele CIS bio international 24. märtsil 2003.
English: These may be substances such as antibodies that have been designed to recognise a particular type of cells in the body, including tumour cells.
Estonian: Nendeks võivad olla ained, näiteks antikehad, mis on ette nähtud teatud liiki rakkude, sealhulgas kasvajarakkude äratundmiseks organismis.
English: Ytracis must not be given directly to any patient.
Estonian: Ytracist ei tohi otseselt manustada mitte ühelegi patsiendile.
English: These medicines act as carrier to take the radioactivity to where it is needed.
Estonian: Need ravimid toimivad kandjatena, viies radioaktiivsuse kohta, kus seda on tarvis.
English: The Committee recommended that Ytracis be given marketing authorisation.
Estonian: Komitee soovitas anda Ytracisele müügiloa.
English: It must be mixed outside the body, usually in a laboratory, with the medicine that needs radiolabelling.
Estonian: See tuleb eelnevalt väljaspool organismi - tavaliselt laboris - segada radiomärgistamist vajava ravimiga.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) YTRACIS EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE YTRACIS Kokkuvõte üldsusele
English: 90Y, yttrium-90, is a radioactive form of the chemical element yttrium.
Estonian: 90Y ehk ütrium-90 on keemilise elemendi ütriumi radioaktiivne vorm.
English: A medicine labelled with Ytracis should not be used in women who are or may be pregnant.
Estonian: Ytracisega märgistatud ravimeid ei tohi kasutada ka rasedad ega need naised, kes võivad olla rasedad.
English: Ytracis is used for radiolabelling.
Estonian: Ytracist kasutatakse radiomärgistamiseks.
English: Ytracis will only be handled and given by people who have experience in the safe handling of radioactive material.
Estonian: Ytracist võivad käidelda ja manustada üksnes radioaktiivse materjali ohutus käitlemises kogenud isikud.
English: The company also presented published information supporting the use of 90Y in radiolabelling other medicines.
Estonian: Lisaks esitas ettevõte varem avaldatud andmed, mis toetavad 90Y kasutamist muude ravimite radiomärgistamiseks.
English: Ytracis is radioactive and its use may carry a risk of cancer and hereditary defects.
Estonian: Ytracis on radioaktiivne ning selle kasutamine võib kätkeda endas vähkkasvaja või pärilike väärarengute tekke riski.
English: The doctor who prescribes Ytracis must ensure that the risks linked to the radioactive exposure are lower than the risks from the disease itself.
Estonian: Ytracist välja kirjutav arst peab eelnevalt veenduma, et radioaktiivse ühendiga kokkupuutest tulenevad ohud on väiksemad kui haigusest endast tingitud ohud.
English: The 90Y contained in Ytracis then attaches itself to the carrier medicine and the resulting mixture is given according to the instructions in the Package Leaflet of the carrier medicine.
Estonian: Ytracises leiduv 90Y kinnitub kandjaravimi külge ning saadud segu manustatakse seejärel vastavalt kandjaravimi pakendi infolehel esitatud juhistele.
English: Medicines radiolabelled with Ytracis should not be used in people who may be hypersensitive (allergic) to yttrium chloride or any of the other ingredients.
Estonian: Ytracisega radiomärgistatud ravimeid ei tohi kasutada patsiendid, kes võivad olla ütriumkloriidi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: What is the risk associated with Ytracis?
Estonian: Millised on Ytracisega kaasnevad riskid?
English: The quantity of Ytracis needed for radiolabelling and the quantity of the radiolabelled medicine that is given will depend on the medicine that is radiolabelled and the disease that is being treated.
Estonian: Radiomärgistamiseks vajalik Ytracise kogus ja manustatava radiomärgistatud ravimi kogus sõltuvad märgistatavast ravimist ja ravitavast haigusest.
English: An example of its use is the treatment of some types of tumours, where the radiolabelled medicine carries the radioactivity to the site of a tumour.
Estonian: Näiteks kasutatakse seda teatavat tüüpi kasvajate raviks, mille puhul radiomärgistatud ravim viib radioaktiivsuse kasvaja asukohta.
English: The information supplied by the company supports the use of Ytracis as a precursor for radiolabelling medicines with 90Y.
Estonian: Ettevõtte esitatud andmed toetavad Ytracise kasutamist eellasena ravimite radiomärgistamiseks 90Y-ga.
English: Why has Ytracis been approved?
Estonian: Miks Ytracis heaks kiideti?
English: In the case of Ytracis, the product is used to label medicines that have been specially developed for use with the active ingredient yttrium (90Y) chloride.
Estonian: Ytracist kasutatakse nende ravimite märgistamiseks, mis on spetsiaalselt välja töötatud kasutamiseks toimeaine ütrium(90Y)kloriidiga.
English: These side effects will depend on the medicine being used, and they will be described in the Package Leaflet of the medicine labelled with Ytracis.
Estonian: Need kõrvalnähud sõltuvad kasutatavast ravimist ning neid kirjeldatakse Ytracisega märgistatud ravimi infolehel.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Ytracis's benefits are greater than its risks for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.
Estonian: Inimravimikomitee jõudis otsusele, et Ytracise kasulikkus spetsiaalselt selle radionukliidiga radiomärgistamiseks välja töötatud ja heaks kiidetud kandjamolekulide radiomärgistamisel on suurem kui sellega kaasnevad riskid.
English: Patients may experience side effects following the injection of the medicine radiolabelled with Ytracis.
Estonian: Patsientidel võib siiski kõrvalnähtusid esineda pärast Ytracisega radiomärgistatud ravimi süstimist.
English: Radiolabelling is a technique where a substance is tagged (labelled) with a radioactive compound.
Estonian: Radiomärgistamine on teatud ainete radioaktiivse ühendiga märgistamise tehnika.
English: Once there, the radioactivity from Ytracis helps to destroy the tumour.
Estonian: Seal aitab Ytracise radioaktiivsus kasvajat hävitada.
English: More information on the restrictions for the medicines radiolabelled with Ytracis will be given in the Package Leaflet of the particular medicine that is radiolabelled with Ytracis.
Estonian: Lisateave Ytracisega radiomärgistatud ravimite kasutamise piirangute kohta esitatakse Ytracisega radiomärgistatavate ravimite pakendi infolehtedel.
English: What is Ytracis used for?
Estonian: Milleks Ytracist kasutatakse?
English: Ytracis is a solution containing the active substance yttrium (90Y) chloride.
Estonian: Ytracis on lahus, mis sisaldab toimeainena ütrium(90Y)kloriidi.
English: Ytracis is never given on its own.
Estonian: Ytracist ei manustata mitte kunagi ainsa ravimina.
English: Other information about Ytracis:
Estonian: Lisateave Ytracise kohta
English: How has Ytracis been studied?
Estonian: Kuidas Ytracist uuriti?
English: How does Ytracis work?
Estonian: Kuidas Ytracis toimib?
English: How is Ytracis used?
Estonian: Kuidas Ytracist kasutatakse?
English: What benefit has Ytracis shown during the studies?
Estonian: Milles seisneb uuringute põhjal Ytracise kasulikkus?
English: The effects of the medicine that is radiolabelled with Ytracis will be fully explained in its Package Leaflet.
Estonian: Ytracisega radiomärgistatud ravimite toimet on põhjalikumalt selgitatud asjaomaste ravimite pakendi infolehtedel.
English: The active substance in Ytracis, yttrium (90Y) chloride, is a radioactive compound.
Estonian: Ytracise toimeaine ütrium(90Y)kloriid on radioaktiivne ühend, mis eraldab beetakiirgust.
English: The full EPAR for Ytracis is available here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Ytracise kohta leiate siit.
English: As Ytracis is a ‘precursor' and will not be given on its own, no studies have been done in humans.
Estonian: Ytracis on prekursor ehk eellane, mida ei manustata kunagi ainsa ravimina.
English: Version 10.1, 06/201902/2016
Estonian: Versioon 10.1, 06/201902/2016 Language rev.1, 04/2016
English: Ask your pharmacist how to throw away medicines you no longer use.
Estonian: Küsige oma apteekrilt, kuidas hävitadavisata ära ravimeid, mida te enam ei kasuta.
English: • <Additional risk minimisation measures>
Estonian: • <Riski minimeerimise lisameetmed>